{"schema_version":"secwatch.filing_event.v1","accession":"0001722482-25-000188","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.778730+00:00","generated_at":"2026-05-17T21:53:25.882920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avantor Q2 net sales $1.68B flat organic; GAAP EPS $0.09; names new CEO","bullets":["Net sales $1.68B (-1% reported, flat organic); net income $64.7M vs $92.9M a year ago.","Diluted GAAP EPS $0.09; adjusted EPS $0.24; adjusted EBITDA $279.8M (16.6% margin).","Lab Solutions sales $1.12B (-3% reported, -1% organic); Bioscience Production $561M (+3%, +2% organic).","CEO transition: Emmanuel Ligner named President & CEO effective Aug 18, succeeds Michael Stubblefield.","Operating cash flow $154M; free cash flow $125M; adjusted net leverage 3.2x."],"urls":{"canonical":"https://secwatch.observer/filing/0001722482-25-000188","json":"https://secwatch.observer/filing/0001722482-25-000188.json","markdown":"https://secwatch.observer/filing/0001722482-25-000188.md","text":"https://secwatch.observer/filing/0001722482-25-000188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/0001722482-25-000188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/avtr-20250801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:53:25.882920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}